FI3166597T3 - Dispergoituva misoprostolitabletti - Google Patents

Dispergoituva misoprostolitabletti

Info

Publication number
FI3166597T3
FI3166597T3 FIEP15750921.7T FI15750921T FI3166597T3 FI 3166597 T3 FI3166597 T3 FI 3166597T3 FI 15750921 T FI15750921 T FI 15750921T FI 3166597 T3 FI3166597 T3 FI 3166597T3
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
use according
seconds
starch
tablet
Prior art date
Application number
FIEP15750921.7T
Other languages
English (en)
Finnish (fi)
Inventor
Sekar Selvaraj
Baskar Elumalai
Malaiarasan Arunachalam
Prabhakaran Venugopal
Original Assignee
Azanta Danmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14176821.8A external-priority patent/EP2965750B1/en
Priority claimed from US14/329,023 external-priority patent/US20160008310A1/en
Application filed by Azanta Danmark As filed Critical Azanta Danmark As
Application granted granted Critical
Publication of FI3166597T3 publication Critical patent/FI3166597T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP15750921.7T 2014-07-11 2015-07-10 Dispergoituva misoprostolitabletti FI3166597T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176821.8A EP2965750B1 (en) 2014-07-11 2014-07-11 Misoprostol dispersible tablet
US14/329,023 US20160008310A1 (en) 2014-07-11 2014-07-11 Misoprostol dispersible tablet
PCT/DK2015/050216 WO2016004960A2 (en) 2014-07-11 2015-07-10 Misoprostol dispersible tablet

Publications (1)

Publication Number Publication Date
FI3166597T3 true FI3166597T3 (fi) 2025-09-16

Family

ID=53879283

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15750921.7T FI3166597T3 (fi) 2014-07-11 2015-07-10 Dispergoituva misoprostolitabletti

Country Status (15)

Country Link
US (2) US11406615B2 (enExample)
EP (1) EP3166597B1 (enExample)
JP (2) JP6532529B2 (enExample)
AU (1) AU2015287186B2 (enExample)
BR (1) BR112017000529A2 (enExample)
CA (1) CA2954086C (enExample)
DK (1) DK3166597T3 (enExample)
EA (1) EA039069B1 (enExample)
FI (1) FI3166597T3 (enExample)
MX (1) MX392771B (enExample)
NZ (1) NZ727876A (enExample)
PL (1) PL3166597T3 (enExample)
RU (1) RU2017104233A (enExample)
TN (1) TN2017000003A1 (enExample)
WO (1) WO2016004960A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434110B (zh) * 2018-04-28 2019-09-10 浙江仙琚制药股份有限公司 米索前列醇组合物、片剂及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB994518A (en) 1962-07-18 1965-06-10 Needle Industries Ltd Improvements relating to shavers
US4301146A (en) * 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US4335097A (en) 1981-01-15 1982-06-15 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and process for the preparation thereof
JPH06199779A (ja) 1992-06-08 1994-07-19 Newpharma Internatl Corp トランス−▲δ２▼−１５−デオキシ−１６−ヒドロキシ−１６−メチル−ｐｇ▲ｅ１▼のメチルエステル（ｂ−４０７）
EP0574185B1 (en) 1992-06-08 1997-09-03 Newpharma International Corporation PGE1 analogs
GB9419566D0 (en) * 1994-09-27 1994-11-16 El Refaey Hazem Oral prostagladins for the routine management of the third stage of labour
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6228213B1 (en) 1997-09-19 2001-05-08 University Of Nebraska-Lincoln Production of microcrystalline cellulose by reactive extrusion
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6526980B1 (en) 1999-08-26 2003-03-04 West Virginia University Cervical drug delivery system
KR20020062323A (ko) * 1999-12-06 2002-07-25 펜웨스트 파머슈티칼즈 컴파니 제약학적 초붕해제
GB2375303A (en) 2001-05-11 2002-11-13 Medical Res Council Method of inducing cervical ripening
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
SI21221A (sl) 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
TW200502000A (en) * 2003-03-28 2005-01-16 Kyowa Hakko Kogyo Kk Dividing tablet
WO2006125450A1 (en) 2005-05-26 2006-11-30 Atef Mohammed Mostafa Darwish Rectal and vaginal suppositories containing misoprostol
WO2006133048A2 (en) 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
EP1906937B1 (en) * 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2007035954A2 (en) 2005-09-23 2007-03-29 Duramed Pharmaceuticals, Inc. Vaginal tablets comprising misoprostol and methods of making and using the same
CN1939308A (zh) 2005-09-28 2007-04-04 应圣俊 一种米索前列醇栓剂
EP1987820A1 (en) 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Slow release misoprostol for obstetric and/or gynaecological applications
EP2572705B1 (en) * 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
WO2010036878A1 (en) 2008-09-26 2010-04-01 The Trustees Of Columbia University In The City Of New York Use of trpv1 receptor agonists in cervical pain and labor
US20120077888A1 (en) 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
US20100260825A1 (en) 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
RU2394814C1 (ru) 2009-05-22 2010-07-20 Учреждение Российской академии наук Институт органической химии Уфимского научного центра РАН Средство, представляющее собой этиловый эфир (±)-11,15-дидезокси-16-метил-16-гидроксипростагландина e1, проявляющее утеротоническую активность
PL2579866T3 (pl) 2010-06-11 2017-01-31 Ferring B.V. Dopochwowe podawanie mizoprostolu
CN102302443B (zh) 2011-09-21 2014-04-23 天津市聚星康华医药科技有限公司 一种米索前列醇阴道缓释栓剂及其制备方法
CN102697746B (zh) * 2012-06-11 2014-03-19 广州朗圣药业有限公司 一种快速融变的米索前列醇阴道用组合物及其制备方法和应用
EP2689781A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol composition
CN104487077A (zh) 2012-07-26 2015-04-01 辉凌公司 米索前列醇制剂
KR20150038174A (ko) 2012-07-26 2015-04-08 훼링 비.브이. 미소프로스톨 조성물
EP2689802A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol formulation
CN102872024B (zh) * 2012-09-28 2015-06-17 天津市聚星康华医药科技有限公司 口腔内使用的米索前列醇药物组合物
CN103040842B (zh) 2012-12-08 2014-11-12 浙江圣博康药业有限公司 一种前列腺素类药物组合物及其制成的前列腺素类药物栓剂
CN103340837B (zh) * 2013-07-08 2018-04-27 天津市聚星康华医药科技有限公司 一种米索前列醇阴道泡腾片及其制备方法

Also Published As

Publication number Publication date
WO2016004960A2 (en) 2016-01-14
JP6532529B2 (ja) 2019-06-19
CA2954086A1 (en) 2016-01-14
AU2015287186A1 (en) 2017-01-19
JP2017520628A (ja) 2017-07-27
EP3166597A2 (en) 2017-05-17
WO2016004960A3 (en) 2016-03-17
RU2017104233A3 (enExample) 2018-12-18
NZ727876A (en) 2018-05-25
JP6921894B2 (ja) 2021-08-18
PL3166597T3 (pl) 2025-11-17
EA039069B1 (ru) 2021-11-30
MX392771B (es) 2025-03-24
DK3166597T3 (en) 2025-09-01
US12005041B2 (en) 2024-06-11
CA2954086C (en) 2020-03-31
AU2015287186B2 (en) 2018-05-31
RU2017104233A (ru) 2018-08-13
US20220347145A1 (en) 2022-11-03
MX2017000399A (es) 2017-08-10
US20210322356A1 (en) 2021-10-21
US11406615B2 (en) 2022-08-09
BR112017000529A2 (pt) 2017-11-14
EP3166597B1 (en) 2025-08-06
EA201692536A1 (ru) 2017-06-30
JP2019147831A (ja) 2019-09-05
TN2017000003A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
RU2014123503A (ru) Лекарственные формы цитрата железа (iii)
HRP20180183T1 (hr) Postupak za proizvodnju farmaceutskog pripravka u obliku tableta s produljenim otpuštanjem koje sadrže pirfenidon i njihova uporaba za regresiju kronične bubrežne insuficijencije, kapsularne kontrakture dojke i fibroze jetre kod ljudi
US9770437B2 (en) Compositions of eltrombopag
EP3348273B1 (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
JP2020527575A5 (enExample)
JP2016108327A5 (enExample)
RU2010101797A (ru) Фармацевтический твердый препарат, содержащий бензазепины и способ его получения
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
NO20090980L (no) Kapecitabin pediatriske tabeletter
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
CN104873458A (zh) 一种沃替西汀冻干口腔崩解片及其制备方法
ATE353635T1 (de) Schnell wasserdispergierbare und domperidon enthaltende tabletten
WO2008107746A3 (en) Tablet comprising microorganisms and a combination of excipients and the manufacture process thereof
CN103127016B (zh) 富马酸比索洛尔片剂组合物及其制备方法
Jain et al. Natural excipients-an alternative to synthetic excipients: a comprehensive review
RU2018126670A (ru) Фармацевтическая композиция для лечения гиперплазии предстательной железы
CN104644598A (zh) 富马酸替诺福韦二吡呋酯片
JP2017520619A5 (enExample)
PE20140379A1 (es) Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparacion, para prevencion y tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal y alfa-d-galactosidasa
RU2014123433A (ru) Способы и композиции для лечения дивертикулёза
CN106214653A (zh) 一种沙芬酰胺缓释片及其制备方法
RU2017126111A (ru) Сложные капсулы, содержащие ралоксифен и витамин D и его производные
CN101890012B (zh) 氨酚氯雷伪麻缓释片及其制备方法
CN103860507B (zh) 一种甲磺酸二氢麦角碱缓释片及其制备方法
Kulkarni et al. Effect of tamarind seed polysaccharide on dissolution behaviour of ibuprofen tablets